CAMP4 Therapeutics Corporation

NASDAQ:CAMP

Biotechnology

Healthcare
$4.10 +2.42%

+$0.10 today

Market cap
$257.29M
Beta
0.08
P/E (TTM)
-2.8
EPS (TTM)
-$1.49
52W Low $1.31High $7.75

Volume 0.19M

Average 0.10M

CAMP Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

CAMP4 Therapeutics CorporationNASDAQ: CAMP

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development declines year over year

Q1 FY2026 research & development of $9.64M fell 5.0% year over year, behind the -3.9% change in trailing-twelve-month research & development. Sequentially, it rose 15.4% from the prior quarter.

Context

  • Research & development amounted to 1092.1% of revenue in FY2025, down 4861.4 pp from a year earlier.
  • Research & development increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -5.0% toward the trailing-twelve-month pace of -3.9%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$9.64M+15.4% QoQ
Last fiscal yearDec 2025
$38.2M-1.6% YoY
LTMMar 2026
$37.7M-3.9% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-5.0%——
1 year-1.6%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
38.2M USD
Year-over-year change
-1.6%
4-year CAGR
+7.7%

Research & Development vs competitors

How CAMP compares with its peers on the latest reported figures

  • Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -3.9% is the 5th highest of 9, against a peer median of -5.0%.
  • Research & development amounts to 958.2% of revenue for CAMP, versus a peer median of 78.3%.
CAMP Competitors
Research & Development for CAMP and competitors
Company Period LTM YoY 3-year CAGR% of revenue
VXRTVaxart, Inc.LTM Mar 2026$200.25M USD+133.0%+35.5%78.3%
PMVPPMV Pharmaceuticals, Inc.LTM Mar 2026$67.7M USD+8.5%+10.6%—
ALXOALX Oncology Holdings Inc.LTM Mar 2026$66.71M USD-38.5%-7.9%—
ACRVAcrivon Therapeutics, Inc. Common StockLTM Mar 2026$59.66M USD-11.8%+35.8%—
ATYRaTyr Pharma, Inc.LTM Mar 2026$55.72M USD+5.5%+12.0%29327.4%
BMEABiomea Fusion, Inc.LTM Mar 2026$48.2M USD-55.0%-0.4%—
CAMPCAMP4 Therapeutics CorporationLTM Mar 2026$37.7M USD-3.9%—958.2%
UNCYUnicycive Therapeutics, Inc.LTM Mar 2026$8.57M USD-44.2%-9.8%—
HYFTMindWalk Holdings Corp.LTM Jan 2026CA$4.56M CAD+1.7%-13.6%24.8%
Peer median (excluding CAMP) —-5.0%+5.1%78.3%

Competitors are the stored peer set for CAMP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Feb 2022
FY2022
Feb 2023
FY2023
Nov 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue295.84M0350K652K3.5M
Cost of Revenue173.95M0001.64M
Gross Profit121.89M(947K)350K652K1.86M
Gross Margin41.2%—100.0%100.0%53.1%
Research & Development28.44M34.77M40.62M38.82M38.2M
Selling, General & Admin100.9M10.23M11.61M14.92M17.36M
Operating Expenses134.76M45M52.23M53.74M53.92M
Depreciation & Amortization22.8M878K1.68M1.7M1.64M
EBITDA7.49M(44.12M)(50.2M)(51.39M)(50.42M)
EBITDA Margin2.5%—-14343.1%-7882.2%-1441.5%
Operating Income(15.31M)(45M)(51.88M)(53.09M)(52.06M)
Operating Margin-5.2%—-14822.6%-8142.3%-1488.3%
Interest Income002.81M1.33M2.17M
Interest Expense15.32M6.26M000
Other Income / Expenses(14.75M)809K2.59M1.3M(28.34M)
Income Before Tax(30.06M)(44.19M)(49.29M)(51.79M)(80.4M)
Pre-Tax Margin-10.2%—-14083.1%-7943.4%-2298.5%
Income Tax Expense1.09M0000
Net Income(31.15M)(44.19M)(49.29M)(51.79M)(80.4M)
Net Margin-10.5%—-14083.1%-7943.4%-2298.5%
EPS (Basic)(0.88)(0.90)(4.07)(2.66)(2.65)
EPS (Diluted)(0.88)(0.90)(4.07)(2.66)(2.65)
Weighted Avg Shares35.25M36.1M12.12M19.51M30.38M
Weighted Avg Shares (Diluted)35.25M36.13M12.12M19.51M30.38M

CAMP4 Therapeutics Corporation

NASDAQ:CAMP

Intrinsic Alpha fair value

Locked

Current Price

$4.10

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.